Athanassios Argiris, MD

Athanassios Argiris, MD, FACP

Contact Dr. Argiris

1025 Walnut Street
College Building, Suite 700
Philadelphia, PA 19107

(215) 955-8875
(215) 503-3408 fax

Most Recent Peer-reviewed Publications

  1. Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal Cancer
  2. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer
  3. Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck
  4. Increased PD-1+and TIM-3+TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients
  5. Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer
  6. Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
  7. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
  8. Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer
  9. Characterization of human papillomavirus antibodies in individuals with head and neck cancer
  10. Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics
  11. Postoperative treatment for head and neck cancer: The emerging role of EGFR-targeted therapy
  12. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors
  13. p53-Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study
  14. CTLA-4+ regulatory t cells increased in cetuximab-treated head and neck cancer patients suppress nk cell cytotoxicity and correlate with poor prognosis
  15. EGFR inhibition for recurrent or metastatic HNSCC
  16. Targeting angiogenesis in head and neck cancer
  17. Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partners
  18. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck
  19. Phase II study of cetuximab in combination with cisplatin and radiation in Unresectable, locally advanced head and neck squamous cell carcinoma: Eastern Cooperative Oncology Group Trial E3303
  20. Erlotinib, erlotinib-sulindac versus placebo: A randomized, double-blind, placebo-controlled window trial in operable head and neck cancer